BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34937728)

  • 1. Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1.
    Ramaswamy M; Kim T; Jones DC; Ghadially H; Mahmoud TI; Garcia A; Browne G; Zenonos Z; Puplampu-Dove Y; Riggs JM; Bhat GK; Herbst R; Schofield DJ; Carlesso G
    Cancer Immunol Res; 2022 Feb; 10(2):200-214. PubMed ID: 34937728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7
    Zhuang X; Long EO
    Cancer Immunol Res; 2019 Jun; 7(6):939-951. PubMed ID: 31018957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
    Sung E; Ko M; Won JY; Jo Y; Park E; Kim H; Choi E; Jung UJ; Jeon J; Kim Y; Ahn H; Choi DS; Choi S; Hong Y; Park H; Lee H; Son YG; Park K; Won J; Oh SJ; Lee S; Kim KP; Yoo C; Song HK; Jin HS; Jung J; Park Y
    Mol Ther; 2022 Aug; 30(8):2800-2816. PubMed ID: 35526096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
    J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
    Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
    J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
    Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
    Dong W; Wu X; Ma S; Wang Y; Nalin AP; Zhu Z; Zhang J; Benson DM; He K; Caligiuri MA; Yu J
    Cancer Discov; 2019 Oct; 9(10):1422-1437. PubMed ID: 31340937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
    Hui E; Cheung J; Zhu J; Su X; Taylor MJ; Wallweber HA; Sasmal DK; Huang J; Kim JM; Mellman I; Vale RD
    Science; 2017 Mar; 355(6332):1428-1433. PubMed ID: 28280247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity.
    Zhong Z; Zhang M; Ning Y; Mao G; Li X; Deng Q; Chen X; Zuo D; Zhao X; Xie E; Wang H; Guo L; Li B; Xiao K; He X
    Sci Rep; 2022 Oct; 12(1):18011. PubMed ID: 36289396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.